
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.

Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Mission: Early cancer detection via fragmentomics-based, ML analysis of cell-free DNA from blood
Founded: 2019
Lead product / tech: DELFI-TF (genome-wide cfDNA fragmentation analysis with machine learning)
Notable financing: $225M Series B (July 18, 2022); total funding reported ~$330.5M
Headcount (approx.): 176 employees
Early cancer detection and treatment monitoring using liquid biopsy (fragmentomics of cell-free DNA).
2019
Biotechnology Research
$225,000,000
Announced Series B to develop portfolio of liquid biopsy tests
“Participation from strategic and institutional investors including Eli Lilly, Point72, Brown Advisory, Menlo Ventures, OrbiMed, Samsara BioCapital, T. Rowe Price, and others”
| Company |
|---|
**About Us
DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.
In our passionate pursuit to radically improve health outcomes, we serve humanity when we:
Lead with Science, Anchor in Pragmatism
: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.
Build With & For All
: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class
Put We over I
: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.
**DELFI has 1-2 designated in-office working days each week for employees who live within within 50 miles of Palo Alto CA or Baltimore MD offices
In the Medical Director/Senior Medical Director (Clinical Development & Medical Affairs) role you will work collaboratively with DELFI clinical development, medical statistics, medical affairs, reimbursement and market access, and externally with clinical experts, guideline organizations, patient advocacy groups, and key opinion leaders to establish understanding of DELFI clinical research and technology. You will also support the generation of product related evidence through review and support of external investigator led studies, and on developing and implementing Real World Evidence generating registries of DELFI technologies in clinical use, focused on enriching the ability of clinicians, payers, and regulatory authorities in the US and abroad. You will play key leadership and participatory roles in DELFI’s own clinical development program including interacting with study sites and collaborating on protocols.
*Medical degree (MD, DO or equivalent) with 5+ years of clinical practice is required for this role*
What you’ll do
What you’ll have accomplished 12 months from now
Executed on DELFI clinical studies, acting as medical monitor, facilitating execution and data interpretation
Lead the preparation of clinical study reports for on-going studies, provide medical input for publications and support Regulatory strategy, including submissions
Provide internal education and clinical insight to help refine DELFI product use applications
Closely monitored and ensured clinical compliance and high scientific standards in ongoing trials
Fostered relationships with KOLs in US and internationally for the assessment of DELFI technology, evidence evaluation and clinical guidelines, including relevant clinically focused advocacy organizations
Supported the launch of at least one investigator initiated study
Presented at several relevant scientific conferences and medical meetings
Provided evidentiary structure and helped design and prepare registry of DELFI technology in real world use
Provided registry guidance for new products
Required
Medical degree (MD, DO or equivalent) with 5+ years of clinical practice
Prior clinical trial implementation experience in Pharma or Medical Devices
Thorough understanding of medical practice and diagnosis related to pulmonology, cancer care or screening
Knowledge of regulatory and GCP elements of clinical trials
Excellent organization, communication, presentation, critical thinking, and interpersonal skills
Ability to influence and build and foster relationships horizontally and vertically across the organization
Ability to communicate with senior leadership, clinicians, and regulatory authorities.
Excellent writing and presentation skills required
Availability for up to 25% business travel
Preferred
Prior experience in vitro diagnostic diagnostics development
An advanced degree in public policy or public health
Molecular diagnostics, genetics, or related scientific field background
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
This position is not eligible for agency partnership. Resumes and outreach from staffing representatives will be declined.
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.
Total Compensation at DELFI is a combination of salary, bonus, equity, and benefits. Actual compensation packages are based on a wide array of factors unique to each candidate, including but not limited to skillset, years & depth of experience, certifications & relevant education, geography.****